{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:50:22Z","timestamp":1789023022232,"version":"build-2803163510"},"reference-count":166,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.xphs.2026.104350","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T23:34:24Z","timestamp":1780443264000},"page":"104350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapeutic monoclonal antibodies in the central nervous system: Pharmacokinetics, bioanalysis and clinical implications"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1650-1937","authenticated-orcid":false,"given":"Isaac G.","family":"Onyango","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruewan","family":"Woolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Stinchcomb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Matveyeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0001","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2026.2614669","article-title":"Antibodies to watch in 2026","volume":"18","author":"Crescioli","year":"2026","journal-title":"MAbs"},{"issue":"3","key":"10.1016\/j.xphs.2026.104350_bib0002","first-page":"197","article-title":"Structure and function of therapeutic antibodies approved by the US FDA in 2024","volume":"8","author":"Strohl","year":"2025","journal-title":"Antib Ther"},{"key":"10.1016\/j.xphs.2026.104350_bib0003","unstructured":"Patient B. Alzheimer\u2019s treatments 2025: here\u2019s every FDA approved therapy; 2025."},{"key":"10.1016\/j.xphs.2026.104350_bib0004","series-title":"Highlights in Alzheimer Disease Research","author":"Advisor","year":"2025"},{"key":"10.1016\/j.xphs.2026.104350_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.549842","article-title":"Natalizumab in multiple sclerosis treatment: from biological effects to immune monitoring","volume":"11","author":"Khoy","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0006","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1756285615615257","article-title":"Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis","volume":"9","author":"Sellebjerg","year":"2016","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.xphs.2026.104350_bib0007","doi-asserted-by":"crossref","DOI":"10.1177\/17562864221142924","article-title":"Comparative effectiveness of natalizumab versus ocrelizumab in multiple sclerosis: a real-world propensity score-matched study","volume":"15","author":"Pape","year":"2022","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"10.1016\/j.xphs.2026.104350_bib0008","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3390\/jnt4040020","article-title":"Enhancing antibody exposure in the Central nervous system: mechanisms of uptake, clearance, and strategies for improved brain delivery","volume":"4","author":"Schwinghamer","year":"2023","journal-title":"J Nanotheranostics"},{"issue":"4","key":"10.1016\/j.xphs.2026.104350_bib0009","first-page":"311","article-title":"Engineering antibody and protein therapeutics to cross the blood-brain barrier","volume":"5","author":"Zhao","year":"2022","journal-title":"Antib Ther"},{"key":"10.1016\/j.xphs.2026.104350_bib0010","series-title":"Physiology, Blood Brain Barrier","article-title":"17 EpimEpim","author":"Gawdi","year":"2023"},{"issue":"12","key":"10.1016\/j.xphs.2026.104350_bib0011","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1007\/s11064-009-0081-y","article-title":"Cellular elements of the blood-brain barrier","volume":"34","author":"Correale","year":"2009","journal-title":"Neurochem Res"},{"key":"10.1016\/j.xphs.2026.104350_bib0012","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.brainresbull.2022.09.017","article-title":"The barrier and interface mechanisms of the brain barrier, and brain drug delivery","volume":"190","author":"Zhang","year":"2022","journal-title":"Brain Res Bull"},{"issue":"8","key":"10.1016\/j.xphs.2026.104350_bib0013","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2310\/JIM.0b013e318276de79","article-title":"Physiology and pathophysiology of the blood-brain barrier: P-glycoprotein and occludin trafficking as therapeutic targets to optimize central nervous system drug delivery","volume":"60","author":"McCaffrey","year":"2012","journal-title":"J Investig Med"},{"issue":"4","key":"10.1016\/j.xphs.2026.104350_bib0014","article-title":"Central nervous system delivery of antibodies and their single-domain antibodies and variable fragment derivatives with focus on intranasal nose to Brain administration","volume":"10","author":"Soleimanizadeh","year":"2021","journal-title":"Antibodies (Basel)"},{"issue":"7","key":"10.1016\/j.xphs.2026.104350_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100204","article-title":"Drug delivery strategies to cross the blood-brain barrier in Alzheimer's disease: a comprehensive review on three promising strategies","volume":"12","author":"de Koning","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"issue":"8","key":"10.1016\/j.xphs.2026.104350_bib0016","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","article-title":"Clinical pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Keizer","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.xphs.2026.104350_bib0017","first-page":"21","article-title":"The cerebrospinal fluid and barriers - anatomic and physiologic considerations","volume":"146","author":"Tumani","year":"2017","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.xphs.2026.104350_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fddev.2023.1227816","article-title":"Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier","volume":"3","author":"Pardridge","year":"2023","journal-title":"Front Drug Deliv"},{"issue":"3","key":"10.1016\/j.xphs.2026.104350_bib0019","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3390\/pharmaceutics14030672","article-title":"Strategies for targeted delivery of exosomes to the brain: advantages and challenges","volume":"14","author":"Choi","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0020","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3390\/pharmaceutics15010093","article-title":"Advanced blood-brain barrier drug delivery","volume":"15","author":"Pardridge","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2026.104350_bib0021","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neuron.2015.11.024","article-title":"Discovery of novel blood-brain barrier targets to enhance brain uptake of therapeutic antibodies","volume":"89","author":"Zuchero","year":"2016","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0022","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55136-4","article-title":"Bi-functional IgG-lysosomal enzyme fusion proteins for brain drug delivery","volume":"9","author":"Boado","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0023","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-83198-w","article-title":"Defining the epitope of a blood-brain barrier crossing single domain antibody specific for the type 1 insulin-like growth factor receptor","volume":"11","author":"Sheff","year":"2021","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.xphs.2026.104350_bib0024","article-title":"Grabody B, an IGF1 receptor-based shuttle, mediates efficient delivery of biologics across the blood-brain barrie","volume":"2","author":"Shin","year":"2022","journal-title":"Cell Rep Methods"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0025","article-title":"CD98hc is a target for brain delivery of biotherapeutics","volume":"14","author":"Becerra","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.xphs.2026.104350_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fddev.2024.1360302","article-title":"Receptor-mediated transcytosis for brain delivery of therapeutics: receptor classes and criteria","volume":"4","author":"Haqqani","year":"2024","journal-title":"Front Drug Deliv"},{"key":"10.1016\/j.xphs.2026.104350_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1214118","article-title":"Site-oriented conjugation of poly(2-methacryloyloxyethyl phosphorylcholine) for enhanced brain delivery of antibody","volume":"11","author":"Ren","year":"2023","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0028","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12887-024-05290-0","article-title":"Administration practices of and adherence to nusinersen in children with spinal muscular atrophy: a multicenter disease registry study in China","volume":"25","author":"Peng","year":"2025","journal-title":"BMC Pediatr"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0029","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/diseases13010017","article-title":"Targeting soluble amyloid oligomers in Alzheimer's Disease: a hypothetical model study comparing intrathecal pseudodelivery of mAbs against intravenous administration","volume":"13","author":"Menendez-Gonzalez","year":"2025","journal-title":"Diseases"},{"issue":"3","key":"10.1016\/j.xphs.2026.104350_bib0030","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/alz.13659","article-title":"Parenchymal CSF fraction is a measure of brain glymphatic clearance and positively associated with amyloid beta deposition on PET","volume":"20","author":"Zhou","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.xphs.2026.104350_bib0031","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s13311-020-00864-z","article-title":"Targeting therapeutic antibodies to the CNS: a comparative study of intrathecal, intravenous, and subcutaneous anti-Nogo A antibody treatment after stroke in rats","volume":"17","author":"Wahl","year":"2020","journal-title":"Neurotherapeutics"},{"issue":"6-7","key":"10.1016\/j.xphs.2026.104350_bib0032","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/1545968318776371","article-title":"First-in-man intrathecal application of neurite growth-promoting anti-nogo-A antibodies in acute spinal cord injury","volume":"32","author":"Kucher","year":"2018","journal-title":"Neurorehabil Neural Repair"},{"key":"10.1016\/j.xphs.2026.104350_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fddev.2025.1644633","article-title":"Strategies for delivering drugs across the blood-brain barrier for the treatment of neurodegenerative diseases","volume":"5","author":"Zhang","year":"2025","journal-title":"Front Drug Deliv"},{"issue":"12","key":"10.1016\/j.xphs.2026.104350_bib0034","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1080\/17425247.2023.2286371","article-title":"Strategies to identify, engineer, and validate antibodies targeting blood-brain barrier receptor-mediated transcytosis systems for CNS drug delivery","volume":"20","author":"Choi","year":"2023","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13036-025-00506-y","article-title":"Engineering FcRn binding kinetics dramatically extends antibody serum half-life and enhances therapeutic potential","volume":"19","author":"Ko","year":"2025","journal-title":"J Biol Eng"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0036","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/s41467-025-57108-x","article-title":"Fc-engineered large molecules targeting blood-brain barrier transferrin receptor and CD98hc have distinct central nervous system and peripheral biodistribution","volume":"16","author":"Khoury","year":"2025","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.xphs.2026.104350_bib0037","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/neuonc\/noae025","article-title":"Distinct uptake and elimination profiles for trastuzumab, human IgG, and biocytin-TMR in experimental HER2+ brain metastases of breast cancer","volume":"26","author":"Silvestri","year":"2024","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.xphs.2026.104350_bib0038","doi-asserted-by":"crossref","DOI":"10.34133\/bmef.0012","article-title":"Nanoparticle targeting with antibodies in the Central nervous system","volume":"4","author":"Lee","year":"2023","journal-title":"BME Front"},{"key":"10.1016\/j.xphs.2026.104350_bib0039","article-title":"Overcoming the blood-brain barrier by using a multistage exosome delivery system to inhibit central nervous system lymphoma","volume":"41","author":"Liu","year":"2022","journal-title":"Nanomedicine"},{"key":"10.1016\/j.xphs.2026.104350_bib0040","first-page":"660","article-title":"Exosome-mediated delivery platform of biomacromolecules into the brain: cetuximab in combination with doxorubicin for glioblastoma therapy","author":"Chu","year":"2024","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2026.104350_bib0041","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1324216","article-title":"Navigating the brain: the role of exosomal shuttles in precision therapeutics","volume":"14","author":"Fatima","year":"2024","journal-title":"Front Neurol"},{"key":"10.1016\/j.xphs.2026.104350_bib0042","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1714390","article-title":"Therapeutic antibody delivery: vector tools to boost efficacy and affordability","volume":"16","author":"Chiyyeadu","year":"2026","journal-title":"Front Immunol"},{"key":"10.1016\/j.xphs.2026.104350_bib0043","first-page":"1","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.xphs.2026.104350_bib0044","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.852003","article-title":"Alpha-synuclein targeting therapeutics for parkinson\u2019s disease and related synucleinopathies","volume":"13","author":"Menon","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.xphs.2026.104350_bib0045","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","article-title":"Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction","volume":"14","author":"Calabresi","year":"2023","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.xphs.2026.104350_bib0046","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3233\/JPD-240207","article-title":"The AAV-\u03b1-synuclein model of parkinson\u2019s disease: an update","volume":"14","author":"Bj\u00f6rklund","year":"2024","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.xphs.2026.104350_bib0047","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.870799","article-title":"AAV vector-mediated antibody delivery (A-MAD) in the central nervous system","volume":"13","author":"Marino","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.xphs.2026.104350_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2025.150047","article-title":"Next-generation neurotherapeutics: mechanistic insights on monoclonal antibodies in Alzheimer\u2019s disease","volume":"1870","author":"Sharma","year":"2026","journal-title":"Brain Res"},{"issue":"39","key":"10.1016\/j.xphs.2026.104350_bib0049","doi-asserted-by":"crossref","first-page":"42290","DOI":"10.18632\/oncotarget.5978","article-title":"Controllable permeability of blood-brain barrier and reduced brain injury through low-intensity pulsed ultrasound stimulation","volume":"6","author":"Su","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0050","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ultrasmedbio.2019.08.024","article-title":"Distribution and diffusion of macromolecule delivery to the brain via focused ultrasound using magnetic resonance and multispectral fluorescence imaging","volume":"46","author":"Valdez","year":"2020","journal-title":"Ultrasound Med Biol"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0051","first-page":"vdab164","article-title":"A phase II study of laser interstitial thermal therapy combined with doxorubicin in patients with recurrent glioblastoma","volume":"3","author":"Butt","year":"2021","journal-title":"Neurooncol Adv"},{"issue":"3","key":"10.1016\/j.xphs.2026.104350_bib0052","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/jps.24309","article-title":"Modulation of intercellular junctions by cyclic-ADT peptides as a method to reversibly increase blood-brain barrier permeability","volume":"104","author":"Laksitorini","year":"2015","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2026.104350_bib0053","doi-asserted-by":"crossref","first-page":"322","DOI":"10.37349\/eds.2024.00049","article-title":"Mechanism of the blood-brain barrier modulation by cadherin peptides","volume":"2","author":"Farokhi","year":"2024","journal-title":"Explor Drug Sci"},{"issue":"9","key":"10.1016\/j.xphs.2026.104350_bib0054","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1021\/acs.molpharmaceut.4c00354","article-title":"Exploring how antibody format drives clearance from the brain","volume":"21","author":"Schwinghamer","year":"2024","journal-title":"Mol Pharm"},{"issue":"18","key":"10.1016\/j.xphs.2026.104350_bib0055","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2021915118","article-title":"Blood-brain barrier opening by intracarotid artery hyperosmolar mannitol induces sterile inflammatory and innate immune responses","volume":"118","author":"Burks","year":"2021","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0056","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41596-021-00634-x","article-title":"Hyperosmolar blood-brain barrier opening using intra-arterial injection of hyperosmotic mannitol in mice under real-time MRI guidance","volume":"17","author":"Chu","year":"2022","journal-title":"Nat Protoc"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0057","first-page":"vdad044","article-title":"Convection-enhanced delivery of immunomodulatory therapy for high-grade glioma","volume":"5","author":"Sperring","year":"2023","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.xphs.2026.104350_bib0058","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1471-2202-9-S3-S5","article-title":"Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease","volume":"9","author":"Hanson","year":"2008","journal-title":"BMC Neurosci"},{"issue":"6","key":"10.1016\/j.xphs.2026.104350_bib0059","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1039\/D5PM00148J","article-title":"Brain-targeted intranasal delivery of biologics: a perspective for Alzheimer's disease treatment","volume":"2","author":"Li","year":"2025","journal-title":"RSC Pharmaceutics"},{"issue":"4","key":"10.1016\/j.xphs.2026.104350_bib0060","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2200057120","article-title":"Intranasal delivery of full-length anti-Nogo-A antibody: A potential alternative route for therapeutic antibodies to central nervous system targets","volume":"120","author":"Correa","year":"2023","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"50","key":"10.1016\/j.xphs.2026.104350_bib0061","doi-asserted-by":"crossref","first-page":"69103","DOI":"10.1021\/acsami.4c18679","article-title":"Effective nose-to-brain delivery of blood-brain barrier impermeant anti-IL-1\u03b2 antibody via the minimally invasive Nasal Depot (MIND) technique","volume":"16","author":"Di Francesco","year":"2024","journal-title":"ACS Appl Mater Interfaces"},{"issue":"3","key":"10.1016\/j.xphs.2026.104350_bib0062","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1007\/s13346-025-01957-y","article-title":"Delivery of monoclonal antibodies to the brain: the impact of nanocarrier structure","volume":"16","author":"Pineiro-Alonso","year":"2026","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.xphs.2026.104350_bib0063","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s13346-025-02043-z","article-title":"Engineering access to the brain: nanotechnologies at the interface of delivery, neurology, and immunotherapy","volume":"16","author":"Merkel","year":"2026","journal-title":"Drug Delivery and Translational Research"},{"key":"10.1016\/j.xphs.2026.104350_bib0064","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.2147\/IJN.S457393","article-title":"Advancing CNS therapeutics: enhancing neurological disorders with nanoparticle-based gene and enzyme replacement therapies","volume":"Volume 20","author":"Liu","year":"2025","journal-title":"Int J Nanomedicine"},{"issue":"5","key":"10.1016\/j.xphs.2026.104350_bib0065","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1080\/19420862.2016.1168956","article-title":"Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GNbAC1 to treat multiple sclerosis: A phase 1 study","volume":"8","author":"Curtin","year":"2016","journal-title":"MAbs"},{"issue":"9","key":"10.1016\/j.xphs.2026.104350_bib0066","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.050836","article-title":"Preclinical evaluation of targeted therapies for central nervous system metastases","volume":"17","author":"Pfeil","year":"2024","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.xphs.2026.104350_bib0067","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.958543","article-title":"Investigating brain uptake of a non-targeting monoclonal antibody after intravenous and intracerebroventricular administration","volume":"13","author":"Van De Vyver","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1-2","key":"10.1016\/j.xphs.2026.104350_bib0068","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jim.2007.07.004","article-title":"An affinity capture elution (ACE) assay for detection of anti\u2011drug antibodies","volume":"327","author":"Bourdage","year":"2007","journal-title":"J Immunol Methods"},{"issue":"7","key":"10.1016\/j.xphs.2026.104350_bib0069","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1515\/cclm-2022-1250","article-title":"Development of a candidate reference measurement procedure by ID-LC-MS\/MS for total tau protein measurement in cerebrospinal fluid (CSF)","volume":"61","author":"Giangrande","year":"2023","journal-title":"Clin Chem Lab Med (CCLM)"},{"key":"10.1016\/j.xphs.2026.104350_bib0070","doi-asserted-by":"crossref","first-page":"958543","DOI":"10.3389\/fphar.2022.958543","article-title":"Investigating brain uptake of a non-targeting monoclonal antibody after intravenous and intracerebroventricular administration","volume":"13","author":"Van De Vyver","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.xphs.2026.104350_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2026.115850","article-title":"Pharmacokinetic modeling to optimize development and therapeutic potential of mAb-based therapies","volume":"233","author":"Fan","year":"2026","journal-title":"Adv Drug Deliv Rev"},{"issue":"9","key":"10.1016\/j.xphs.2026.104350_bib0072","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of monoclonal antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"10.1016\/j.xphs.2026.104350_bib0073","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/cts.12567","article-title":"Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development","volume":"11","author":"Ovacik","year":"2018","journal-title":"Clin Transl Sci"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0074","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.dmpk.2018.11.002","article-title":"Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development","volume":"34","author":"Glassman","year":"2019","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.xphs.2026.104350_bib0075","unstructured":"ICH. ICH M10: bioanalytical method validation; Published 2022."},{"issue":"6","key":"10.1016\/j.xphs.2026.104350_bib0076","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nbt.1641","article-title":"Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations","volume":"28","author":"Rissin","year":"2010","journal-title":"Nat Biotechnol"},{"issue":"2","key":"10.1016\/j.xphs.2026.104350_bib0077","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4155\/bio.12.299","article-title":"Bioanalytical Assay Strategies for The Development of Antibody\u2013Drug Conjugate Biotherapeutics","volume":"5","author":"Kaur","year":"2013","journal-title":"Bioanalysis"},{"issue":"14","key":"10.1016\/j.xphs.2026.104350_bib0078","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.4155\/bio-2017-0084","article-title":"Parallelism experiments to evaluate matrix effects, selectivity and sensitivity in ligand-binding assay method development: pros and cons","volume":"9","author":"Tu","year":"2017","journal-title":"Bioanalysis"},{"issue":"7","key":"10.1016\/j.xphs.2026.104350_bib0079","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s00216-020-02403-3","article-title":"Investigating surrogate cerebrospinal fluid matrix compositions for use in quantitative LC-MS analysis of therapeutic antibodies in the cerebrospinal fluid","volume":"412","author":"Fogh","year":"2020","journal-title":"Anal Bioanal Chem"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0080","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22625","article-title":"Application of an electrochemiluminescence assay for quantification of E6011, an antifractalkine monoclonal antibody, to pharmacokinetic studies in monkeys and humans","volume":"33","author":"Aoyama","year":"2019","journal-title":"J Clin Lab Anal"},{"issue":"3","key":"10.1016\/j.xphs.2026.104350_bib0081","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3233\/JAD-143099","article-title":"Diagnostic values of cerebrospinal fluid T-tau and a\u03b2\u2084\u2082 using Meso Scale Discovery assays for Alzheimer's Disease","volume":"45","author":"Pan","year":"2015","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0082","article-title":"Diagnosing Alzheimer's disease: which dementia screening test to use in elderly Puerto Ricans with mild cognitive impairment and early Alzheimer's disease?","volume":"16","author":"Rodr\u00edguez-Santiago","year":"2024","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.1016\/j.xphs.2026.104350_bib0083","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-1-0716-4462-1_3","article-title":"Application of single molecule array (SIMOA) in cerebrospinal fluid","volume":"2914","author":"Anaya-Cubero","year":"2025","journal-title":"Methods Mol Biol"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0084","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1038\/s41598-023-29704-8","article-title":"Neurofilament-light chain quantification by Simoa and Ella in plasma from patients with dementia: a comparative study","volume":"13","author":"Truffi","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.xphs.2026.104350_bib0085","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-1-0716-4462-1_7","article-title":"Cerebrospinal fluid phosphoproteome characterization using titanium dioxide enrichment and high-resolution LC-MS\/MS","volume":"2914","author":"Anaya-Cubero","year":"2025","journal-title":"Methods Mol Biol"},{"issue":"6","key":"10.1016\/j.xphs.2026.104350_bib0086","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0269157","article-title":"An immuno-enrichment free, validated quantification of tau protein in human CSF by LC-MS\/MS","volume":"17","author":"Self","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.xphs.2026.104350_bib0087","first-page":"4931","article-title":"Quantitation of therapeutic proteins in biological matrices using LC MS\/MS: advances and challenges","volume":"78","author":"Zhang","year":"2006","journal-title":"Anal Chem"},{"issue":"12","key":"10.1016\/j.xphs.2026.104350_bib0088","first-page":"1077","article-title":"LC-MS\/MS for the quantitation of therapeutic monoclonal antibodies via signature peptides","volume":"5","author":"Jiang","year":"2013","journal-title":"Bioanalysis"},{"issue":"4","key":"10.1016\/j.xphs.2026.104350_bib0089","first-page":"1528","article-title":"Multiplexed LC-MS\/MS quantitation of monoclonal antibodies using signature peptides","volume":"84","author":"Duan","year":"2012","journal-title":"Anal Chem"},{"issue":"6","key":"10.1016\/j.xphs.2026.104350_bib0090","first-page":"1353","article-title":"LC-MS\/MS strategies for quantifying therapeutic antibodies in complex matrices","volume":"19","author":"Wang","year":"2017","journal-title":"AAPS J"},{"issue":"14","key":"10.1016\/j.xphs.2026.104350_bib0091","doi-asserted-by":"crossref","first-page":"8421","DOI":"10.1021\/acs.analchem.8b00984","article-title":"Accurate sequence analysis of a monoclonal antibody by top-down and middle-down orbitrap mass spectrometry","volume":"90","author":"Fornelli","year":"2018","journal-title":"Anal Chem"},{"issue":"5","key":"10.1016\/j.xphs.2026.104350_bib0092","first-page":"782","article-title":"Immunoaffinity enrichment coupled with MALDI mass spectrometry for targeted protein quantitation","volume":"26","author":"Greer","year":"2015","journal-title":"J Am Soc Mass Spectrom"},{"issue":"2","key":"10.1016\/j.xphs.2026.104350_bib0093","first-page":"103","article-title":"Hybrid immunoaffinity-mass spectrometry approaches for quantifying therapeutic antibodies in biological matrices","volume":"12","author":"Liu","year":"2020","journal-title":"Bioanalysis"},{"issue":"4","key":"10.1016\/j.xphs.2026.104350_bib0094","doi-asserted-by":"crossref","first-page":"414","DOI":"10.14283\/jpad.2021.56","article-title":"Donanemab (LY3002813) Phase 1b study in Alzheimer's Disease: rapid and sustained reduction of brain amyloid measured by Florbetapir F18 imaging","volume":"8","author":"Lowe","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"issue":"2","key":"10.1016\/j.xphs.2026.104350_bib0095","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1352458508098268","article-title":"Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders","volume":"15","author":"Petereit","year":"2009","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.xphs.2026.104350_bib0096","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/cpt.2531","article-title":"Translational approaches for brain delivery of biologics via cerebrospinal fluid","volume":"111","author":"Sadekar","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.xphs.2026.104350_bib0097","article-title":"The penetration of therapeutics across the blood-brain barrier: classic case studies and clinical implications","volume":"5","author":"Banks","year":"2024","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0098","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-018-0359-x","article-title":"White paper by the Society for CSF Analysis and Clinical Neurochemistry: overcoming barriers in biomarker development and clinical translation","volume":"10","author":"Teunissen","year":"2018","journal-title":"Alzheimers Res Ther"},{"issue":"8","key":"10.1016\/j.xphs.2026.104350_bib0099","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1002\/alz.12970","article-title":"Pathogenesis of Alzheimer's disease: involvement of the choroid plexus","volume":"19","author":"\u010carna","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"5","key":"10.1016\/j.xphs.2026.104350_bib0100","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/brain\/awad031","article-title":"Cerebrospinal fluid immunoglobulins in primary progressive multiple sclerosis are pathogenic","volume":"146","author":"Wong","year":"2023","journal-title":"Brain"},{"issue":"261","key":"10.1016\/j.xphs.2026.104350_bib0101","doi-asserted-by":"crossref","first-page":"261ra154","DOI":"10.1126\/scitranslmed.3009835","article-title":"Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates","volume":"6","author":"Yu","year":"2014","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.xphs.2026.104350_bib0102","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1208\/s12248-024-00898-7","article-title":"Investigation of antibody pharmacokinetics in the brain following intra-CNS administration and development of PBPK model to characterize the data","volume":"26","author":"Wu","year":"2024","journal-title":"AAPS J"},{"issue":"6","key":"10.1016\/j.xphs.2026.104350_bib0103","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s10928-021-09776-7","article-title":"Minimal brain PBPK model to support the preclinical and clinical development of antibody therapeutics for CNS diseases","volume":"48","author":"Bloomingdale","year":"2021","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"11","key":"10.1016\/j.xphs.2026.104350_bib0104","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40262-019-00790-0","article-title":"Requirements to establishing confidence in physiologically based pharmacokinetic (PBPK) models and overcoming some of the challenges to meeting them","volume":"58","author":"Peters","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0105","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2515414","article-title":"Translational minimal physiologically based pharmacokinetic model for transferrin receptor-mediated brain delivery of antibodies","volume":"17","author":"Muliaditan","year":"2025","journal-title":"MAbs"},{"key":"10.1016\/j.xphs.2026.104350_bib0106","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.867457","article-title":"PBPK-PD modeling for the preclinical development and clinical translation of tau antibodies for Alzheimer's disease","volume":"13","author":"Bloomingdale","year":"2022","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.xphs.2026.104350_bib0107","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10928-019-09641-8","article-title":"A translational platform PBPK model for antibody disposition in the brain","volume":"46","author":"Chang","year":"2019","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"6","key":"10.1016\/j.xphs.2026.104350_bib0108","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1023\/A:1014414520282","article-title":"General pharmacokinetic model for drugs exhibiting target-mediated drug disposition","volume":"28","author":"Mager","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"12","key":"10.1016\/j.xphs.2026.104350_bib0109","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1002\/psp4.13224","article-title":"Population pharmacokinetics and exposure-response analyses of safety (ARIA-E and isolated ARIA-H) of lecanemab in subjects with early Alzheimer's disease","volume":"13","author":"Majid","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"10.1016\/j.xphs.2026.104350_bib0110","doi-asserted-by":"crossref","DOI":"10.1002\/psp4.70160","article-title":"A tutorial on the development of a physiologically inspired PKRO model for monoclonal antibodies","volume":"15","author":"Kapitanov","year":"2026","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"9","key":"10.1016\/j.xphs.2026.104350_bib0111","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1111\/bcp.13996","article-title":"Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology","volume":"85","author":"Bajaj","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2026.104350_bib0112","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2024.1412006","article-title":"Three major effects of APOE\u03b54 on a\u03b2 immunotherapy induced ARIA","volume":"16","author":"Foley","year":"2024","journal-title":"Front Aging Neurosci"},{"issue":"9","key":"10.1016\/j.xphs.2026.104350_bib0113","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/psp4.12538","article-title":"Phase II dose selection for alpha synuclein-targeting antibody cinpanemab (BIIB054) based on target protein binding levels in the brain","volume":"9","author":"Kuchimanchi","year":"2020","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"12","key":"10.1016\/j.xphs.2026.104350_bib0114","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/psp4.12862","article-title":"Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease","volume":"11","author":"Hayato","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"3","key":"10.1016\/j.xphs.2026.104350_bib0115","article-title":"Lecanemab reduces brain amyloid-\u03b2 and delays cognitive worsening","volume":"4","author":"Knopman","year":"2023","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0116","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00415-020-10362-z","article-title":"Rituximab for the treatment of multiple sclerosis: a review","volume":"269","author":"Chisari","year":"2022","journal-title":"J Neurol"},{"issue":"1-2","key":"10.1016\/j.xphs.2026.104350_bib0117","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jneuroim.2006.06.029","article-title":"Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients","volume":"180","author":"Cross","year":"2006","journal-title":"J Neuroimmunol"},{"issue":"4","key":"10.1016\/j.xphs.2026.104350_bib0118","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrd.2015.21","article-title":"From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery","volume":"15","author":"Banks","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.xphs.2026.104350_bib0119","first-page":"11","article-title":"Blood-brain barrier and delivery of protein and gene therapeutics to brain","author":"Pardridge","year":"2020","journal-title":"Front Aging Neurosci"},{"issue":"6","key":"10.1016\/j.xphs.2026.104350_bib0120","first-page":"553","article-title":"PBPK modeling for large molecules: a mechanistic framework for monoclonal antibody disposition","volume":"46","author":"Zhao","year":"2019","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"11","key":"10.1016\/j.xphs.2026.104350_bib0121","first-page":"765","article-title":"Predicting drug concentration\u2010time profiles in multiple CNS compartments using a comprehensive physiologically\u2010based pharmacokinetic model","volume":"6","author":"Yamamoto","year":"2017","journal-title":"CPT: Pharmacomet Syst Pharmacol"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0122","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12987-018-0093-6","article-title":"Monoclonal antibody exposure in rat and cynomolgus monkey cerebrospinal fluid following systemic administration","volume":"15","author":"Wang","year":"2018","journal-title":"Fluids Barriers CNS"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0123","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2229098","article-title":"Modifying antibody-FcRn interactions to increase the transport of antibodies through the blood-brain barrier","volume":"15","author":"Tien","year":"2023","journal-title":"MAbs"},{"issue":"14","key":"10.1016\/j.xphs.2026.104350_bib0124","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.88034","article-title":"Glymphatic fluid transport controls paravascular clearance of AAV vectors from the brain","volume":"1","author":"Murlidharan","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.xphs.2026.104350_bib0125","unstructured":"ICH. M15 General principles for model-informed drug development; 2024."},{"issue":"8","key":"10.1016\/j.xphs.2026.104350_bib0126","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s11095-022-03288-w","article-title":"Review: role of model-informed drug development approaches in the lifecycle of drug development and regulatory decision-making","volume":"39","author":"Madabushi","year":"2022","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2026.104350_bib0127","unstructured":"FDA. Monoclonal antibodies: streamlined nonclinical safety studies (Draft Guidance); 2025."},{"key":"10.1016\/j.xphs.2026.104350_bib0128","series-title":"Clinical Pharmacology Considerations for the Development of Therapeutic Proteins. Draft Guidance for Industry","year":"2008"},{"key":"10.1016\/j.xphs.2026.104350_bib0129","series-title":"Drug-Drug Interaction Assessment for Therapeutic Proteins. Guidance for Industry","year":"2023"},{"key":"10.1016\/j.xphs.2026.104350_bib0130","series-title":"Monoclonal Antibodies: Streamlined Nonclinical Safety Studies. Draft Guidance for Industry","year":"2025"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0131","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70125","article-title":"Navigating recent changes in dosing information: dynamics of FDA-approved monoclonal antibodies in post-marketing realities","volume":"18","author":"Lee","year":"2025","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.xphs.2026.104350_bib0132","article-title":"Humanized bispecific antibodies for improved amyloid \u03b2 detection and brain uptake","volume":"8","author":"Hultqvist","year":"2017","journal-title":"Nature Commun"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0133","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuron.2013.10.061","article-title":"Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle","volume":"81","author":"Niewoehner","year":"2014","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0134","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12987-020-00230-3","article-title":"A blood\u2013brain barrier overview on structure, function, impairment, and biomarkers of integrity","volume":"17","author":"Kadry","year":"2020","journal-title":"Fluids Barriers CNS"},{"issue":"2","key":"10.1016\/j.xphs.2026.104350_bib0135","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-018-0297-y","article-title":"Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction","volume":"25","author":"Nation","year":"2019","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.xphs.2026.104350_bib0136","first-page":"143","article-title":"Advances in LC\u2013MS\/MS bioanalysis for low abundance biomolecules in CNS matrices","volume":"14","author":"O\u2019Connell","year":"2022","journal-title":"Bioanalysis"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0137","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-020-00663-w","article-title":"Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval","volume":"12","author":"Tolar","year":"2020","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0138","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0139","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/healthcare11010032","article-title":"Donanemab for Alzheimer's disease: a systematic review of clinical trials","volume":"11","author":"Rashad","year":"2022","journal-title":"Healthcare (Basel)"},{"issue":"6","key":"10.1016\/j.xphs.2026.104350_bib0140","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0141","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2261509","article-title":"Delivery of the Brainshuttle\u2122 amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans","volume":"15","author":"Grimm","year":"2023","journal-title":"MAbs"},{"issue":"10","key":"10.1016\/j.xphs.2026.104350_bib0142","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","article-title":"Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti-\u03b1-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial","volume":"75","author":"Jankovic","year":"2018","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0143","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00415-024-12770-x","article-title":"An update on immune-based alpha-synuclein trials in Parkinson's disease","volume":"272","author":"Alfaidi","year":"2024","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0144","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41531-025-01117-6","article-title":"A brain-shuttled antibody targeting alpha synuclein aggregates for the treatment of synucleinopathies","volume":"11","author":"An","year":"2025","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.xphs.2026.104350_bib0145","doi-asserted-by":"crossref","DOI":"10.1177\/17562864221150040","article-title":"Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis","volume":"16","author":"Callegari","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.xphs.2026.104350_bib0146","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1290666","article-title":"Bioavailable central nervous system disease-modifying therapies for multiple sclerosis","volume":"14","author":"Hartung","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0147","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcae021","article-title":"Ocrelizumab associates with reduced cerebrospinal fluid B and CD20dim CD4+ T cells in primary progressive multiple sclerosis","volume":"6","author":"van Puijfelik","year":"2024","journal-title":"Brain Commun"},{"key":"10.1016\/j.xphs.2026.104350_bib0148","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.77146","article-title":"Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target - an fMRI study","volume":"11","author":"Basedau","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.xphs.2026.104350_bib0149","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1212\/WNL.0000000000205261","article-title":"Measurement and modeling of peripherally administered anti-CGRP monoclonal antibody in CSF and brain of healthy volunteers (S22.006)","volume":"102","author":"Rorabaugh","year":"2024","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.xphs.2026.104350_bib0150","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1177\/0333102419844711","article-title":"Peripheral and central nervous system distribution of the CGRP neutralizing antibody [125I] galcanezumab in male rats","volume":"9","author":"Johnson","year":"2019","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0151","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/s12883-023-03368-3","article-title":"Correction: rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial","volume":"23","author":"Ailani","year":"2023","journal-title":"BMC Neurol"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0152","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1148\/radiol.2016152444","article-title":"Focused ultrasound enhances Central nervous system delivery of Bevacizumab for malignant glioma treatment","volume":"281","author":"Liu","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.xphs.2026.104350_bib0153","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.696387","article-title":"Eculizumab pharmacokinetics and pharmacodynamics in patients with Neuromyelitis Optica spectrum disorder","volume":"12","author":"Singh","year":"2021","journal-title":"Front Neurol"},{"issue":"10","key":"10.1016\/j.xphs.2026.104350_bib0154","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s40263-022-00949-7","article-title":"Inebilizumab: a review in Neuromyelitis Optica spectrum disorder","volume":"36","author":"Nie","year":"2022","journal-title":"CNS Drugs"},{"issue":"14","key":"10.1016\/j.xphs.2026.104350_bib0155","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s40265-023-01933-1","article-title":"Rozanolixizumab: first approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.xphs.2026.104350_bib0156","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s40265-025-02211-y","article-title":"Nipocalimab: first approval","volume":"85","author":"Fung","year":"2025","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.xphs.2026.104350_bib0157","doi-asserted-by":"crossref","first-page":"7891","DOI":"10.1097\/MS9.0000000000004103","article-title":"Nipocalimab: a significant milestone in the treatment of myasthenia gravis approved by the FDA","volume":"87","author":"Irfan","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"issue":"2","key":"10.1016\/j.xphs.2026.104350_bib0159","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1021\/acs.molpharmaceut.5c00956","article-title":"Targeting hyaluronic acid increases brain retention of intraventricular dosed antibodies in mice","volume":"23","author":"Schwinghamer","year":"2026","journal-title":"Mol Pharm"},{"issue":"12","key":"10.1016\/j.xphs.2026.104350_bib0160","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.3390\/pharmaceutics13122014","article-title":"Current and emerging strategies for enhancing antibody delivery to the brain","volume":"13","author":"Bajracharya","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0161","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12035-025-05417-z","article-title":"Targeted nanoparticles for drug delivery across the blood-brain barrier in early and late stages of Alzheimer's Disease: A review","volume":"63","author":"Kochman","year":"2025","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.xphs.2026.104350_bib0162","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2026.1759915","article-title":"Application of nanoparticles in antibody drug delivery","volume":"14","author":"Xiefukaiti","year":"2026","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"10.1016\/j.xphs.2026.104350_bib0163","article-title":"Aducanumab delivery via focused ultrasound-induced transient blood-brain barrier opening in vivo","volume":"15","author":"Jeong","year":"2025","journal-title":"Sci Rep"},{"issue":"13","key":"10.1016\/j.xphs.2026.104350_bib0164","article-title":"Focused ultrasound enhanced antibody delivery for the treatment of Parkinson\u2019s Disease","volume":"09","author":"Kwon","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.xphs.2026.104350_bib0165","article-title":"Combination of neuronavigation-guided focused ultrasound and Bevacizumab for patients with recurrent glioblastoma: a pilot study","author":"Chen","year":"2025","journal-title":"Neurosurgery"},{"issue":"5","key":"10.1016\/j.xphs.2026.104350_bib0166","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/jnc.14332","article-title":"Delivery of an anti-transthyretin nanobody to the brain through intranasal administration reveals transthyretin expression and secretion by motor neurons","volume":"145","author":"Gomes","year":"2018","journal-title":"J Neurochem"},{"key":"10.1016\/j.xphs.2026.104350_bib0167","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.3389\/fphar.2020.01165","article-title":"Intranasal delivery of targeted nanoparticles loaded with miR-132 to brain for the treatment of neurodegenerative diseases","volume":"11","author":"Su","year":"2020","journal-title":"Front Pharmacol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926001991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926001991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:34:13Z","timestamp":1788507253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926001991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":166,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0022354926001991"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104350","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic monoclonal antibodies in the central nervous system: Pharmacokinetics, bioanalysis and clinical implications","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104350","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104350"}}